From a single serum sample, we quantify multiple biomarkers — known and newly discovered. Advanced. Automated. Affordable.
Learn more
FDA-cleared AXINON®System is our core technology platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.
GFR — One of the most important markers for identifying impaired renal function
Currently, GFR is based on an estimation using clinical data and blood-based biomarkers, like creatinine or cystatin C. GFR can either be measured (mGFR) by tracer methods or estimated (eGFR).
mGFR methods are elaborate and time-consuming, and eGFR lacks accuracy in a number of common clinical situations. Because of this, clinical decision-making is difficult, especially early when intervention may help slow progression to end-stage renal disease.
1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.
This new kidney function assay combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.
A single result from this biomarker constellation generates a more accurate GFR result compared to standard eGFR equations.
Selected Publications
Meeusen J, Stämmler F, Dasari S, et al. (2022). Front. Med. 9:988989.
Fuhrmann M, Santamaria A, Scott, R, et al. (2022). Diagnostics 2022, 12(5), 1120.
Stämmler F, Grassi M, Meeusen JW, et al. (2021). Diagnostics (Basel). 2021 Dec 7;11(12):2291.
Ehrich J, Dubourg L, Hansson S, et al. (2021). Diagnostics (Basel). 2021 Feb 3;11(2):234
Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level.
For GFR(NMR), the generated signals from serum samples corresponds with concentrations of the targeted metabolites with results reported in mL/minute/1.73 m2.
Our FDA-cleared AXINON® System is the core technology platform we use to develop diagnostic tests for illnesses stemming from metabolic dysfunction, including chronic heart, kidney and liver diseases. This system incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for precise results.
To date, more than 3 million tests have been performed worldwide using Numares technology.
* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.
